alendronate + zoledronate

Sequential therapy of alendronate and zoledronate is a treatment regimen being evaluated by National Taiwan University Hospital to mitigate the rapid bone loss observed after discontinuing denosumab in patients with osteoporosis. Both drugs are nitrogen-containing bisphosphonates that bind to hydroxyapatite in bone and are internalized by osteoclasts. Once inside, they inhibit farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This inhibition prevents the prenylation of small GTP-binding proteins essential for osteoclast function and survival, ultimately leading to reduced bone resorption and stabilization of bone mineral density.

Other names

alendronate and zoledronate sequential therapy